Cytokinetics (CYTK) Capital Expenditures (2016 - 2025)
Historic Capital Expenditures for Cytokinetics (CYTK) over the last 15 years, with Q4 2024 value amounting to $1.3 million.
- Cytokinetics' Capital Expenditures rose 157532.47% to $1.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.9 million, marking a year-over-year increase of 17584.75%. This contributed to the annual value of $3.9 million for FY2024, which is 17584.75% up from last year.
- Latest data reveals that Cytokinetics reported Capital Expenditures of $1.3 million as of Q4 2024, which was up 157532.47% from $701000.0 recorded in Q3 2024.
- Cytokinetics' 5-year Capital Expenditures high stood at $17.8 million for Q4 2021, and its period low was $77000.0 during Q4 2023.
- For the 5-year period, Cytokinetics' Capital Expenditures averaged around $3.8 million, with its median value being $1.8 million (2022).
- As far as peak fluctuations go, Cytokinetics' Capital Expenditures surged by 162800.0% in 2020, and later plummeted by 9759.75% in 2023.
- Cytokinetics' Capital Expenditures (Quarter) stood at $6.6 million in 2020, then soared by 170.85% to $17.8 million in 2021, then crashed by 81.95% to $3.2 million in 2022, then plummeted by 97.6% to $77000.0 in 2023, then soared by 1575.32% to $1.3 million in 2024.
- Its last three reported values are $1.3 million in Q4 2024, $701000.0 for Q3 2024, and $161000.0 during Q2 2024.